1. Altered neuronal network and rescue in a human MECP2 duplication model
- Author
-
Nageshappa, S, Carromeu, C, Trujillo, CA, Mesci, P, Espuny-Camacho, I, Pasciuto, E, Vanderhaeghen, P, Verfaillie, CM, Raitano, S, Kumar, A, Carvalho, CMB, Bagni, C, Ramocki, MB, Araujo, BHS, Torres, LB, Lupski, JR, Van Esch, H, and Muotri, AR
- Subjects
Biomedical and Clinical Sciences ,Neurosciences ,Stem Cell Research - Nonembryonic - Human ,Orphan Drug ,Stem Cell Research - Induced Pluripotent Stem Cell - Human ,Neurodegenerative ,Rett Syndrome ,Stem Cell Research - Induced Pluripotent Stem Cell ,Rare Diseases ,Stem Cell Research ,Genetics ,Brain Disorders ,Pediatric ,Stem Cell Research - Embryonic - Human ,Intellectual and Developmental Disabilities (IDD) ,5.1 Pharmaceuticals ,Development of treatments and therapeutic interventions ,Neurological ,Cell Differentiation ,Dendrites ,Gene Dosage ,Gene Duplication ,Genetic Association Studies ,Humans ,Induced Pluripotent Stem Cells ,Male ,Methyl-CpG-Binding Protein 2 ,Nerve Net ,Neurogenesis ,Neurons ,Biological Sciences ,Medical and Health Sciences ,Psychology and Cognitive Sciences ,Psychiatry ,Clinical sciences ,Biological psychology ,Clinical and health psychology - Abstract
Increased dosage of methyl-CpG-binding protein-2 (MeCP2) results in a dramatic neurodevelopmental phenotype with onset at birth. We generated induced pluripotent stem cells (iPSCs) from patients with the MECP2 duplication syndrome (MECP2dup), carrying different duplication sizes, to study the impact of increased MeCP2 dosage in human neurons. We show that cortical neurons derived from these different MECP2dup iPSC lines have increased synaptogenesis and dendritic complexity. In addition, using multi-electrodes arrays, we show that neuronal network synchronization was altered in MECP2dup-derived neurons. Given MeCP2 functions at the epigenetic level, we tested whether these alterations were reversible using a library of compounds with defined activity on epigenetic pathways. One histone deacetylase inhibitor, NCH-51, was validated as a potential clinical candidate. Interestingly, this compound has never been considered before as a therapeutic alternative for neurological disorders. Our model recapitulates early stages of the human MECP2 duplication syndrome and represents a promising cellular tool to facilitate therapeutic drug screening for severe neurodevelopmental disorders.
- Published
- 2016